Semaglutide promotes weight loss in patients with type 2 diabetes

Glucagon-like peptide-1 receptor agonist (GLP-1RA) is a hot spot in the research and development of hypoglycemic drugs in recent years. Semaglutide, which has just been marketed in my country, belongs to GLP-1RA weekly preparations, which takes into account the comprehensive benefits of potent hypoglycemic and cardiovascular metabolism. At present, it has been approved in China for two indications: suitable for diet control and exercise. Adult type 2 diabetes mellitus (T2DM) patients who receive metformin and/or sulfonylureas for treatment of poor blood glucose control; suitable for reducing major cardiovascular adverse events (cardiovascular death, non-fatality) in adult T2DM patients with cardiovascular disease Myocardial infarction or non-fatal stroke) risk.

Semaglutide regulates blood sugar by increasing glucose-dependent insulin secretion, reducing glucagon secretion, delaying early gastric emptying, reducing food intake and other mechanisms to regulate blood sugar, effectively lowering blood sugar, and bringing multiple gains in cardiovascular metabolism. beneficial.

Semaglutide innovative peptide chain structure modification, has 94% homology with natural human GLP-1, prolongs the half-life in vivo to 7 days, and can be administered once a week. Semaglutide is easy to use, starting with a small dose, and then gradually increasing the dose. Semaglutide has no specific metabolic organs, and there is no need to adjust the dose in patients with mild, moderate, or severe liver and kidney damage. There is no need to adjust the dose of semaglutide based on factors such as age, gender, race, race, and injection site. There is no need to adjust the dose when semaglutide is used in combination with metformin, atorvastatin, digoxin, warfarin and other drugs.

Semaglutide is a glucagon-like peptide-1 receptor agonist. It increases the production of insulin, a hormone that lowers the blood sugar level.It also appears to enhance growth of β cells in the pancreas, which are the sites of insulin production.It also inhibits glucagon, which is a hormone that increases blood sugar. It additionally reduces food intake by lowering appetite and slows down digestion in the stomach.In this way it reduces body fat.